GMP Cryopreserved PBMCs
COMING SOON
The high cost and risk of manufacturing failures in cell and gene therapy (CGT) pose significant challenges for timely production and delivery of safe, effective, and reliable allogeneic therapies to patients. Discovery’s AllCells® GMP Cryopreserved Peripheral Blood Mononuclear Cells (PBMCs) address these challenges by overcoming logistical and target cell isolation bottlenecks. Access to characterized, high-quality, GMP PBMCs minimizes manufacturing risks, enhances overall process efficiency, which results in cost-savings across development and commercialization.
With an agile team and advanced infrastructure, Discovery has supported many complex CGT programs. We specialize in developing tailored solutions that allow our clients to confidently translate and scale their CGT programs.
Why Choose AllCells® GMP Cryopreserved PBMCs?
- Discovery maintains full control over the entire donor process from donor screening and leukapheresis collection to cell processing and cryopreservation.
- Leukapheresis collections from donors are processed in an ISO 7 cleanroom and PBMCs are isolated in a closed system.
- Our integrated donor clinic and processing lab ensure minimal time between collection, processing, and cryopreservation, preserving cell quality and reducing logistical hurdles.
- Clients can pre-screen off-the-shelf PBMC lots to predict downstream cell performance without the need for a Statement of Work (SOW) or Master Service Agreement (MSA).